2CB-5-EtO
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2CB-5-EtO, also known as 2-methoxy-5-ethoxy-4-bromophenethylamine, is a psychoactive drug of the phenethylamine, 2C, and TWEETIO families related to the psychedelic drug 2C-B.[1][5] It is the derivative of 2C-B in which the methoxy group at the 5 position has been replaced with an ethoxy group.[1]
- None
| |
| Clinical data | |
|---|---|
| Other names | 2CB-5EtO; 2CB-5-ETO; 2CB-5ETO; 2C-B-5-EtO; 2-Methoxy-5-ethoxy-4-bromophenethylamine; 2-Methoxy-4-bromo-5-ethoxyphenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1][2][3][4] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H16BrNO2 |
| Molar mass | 274.158 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Unlike other TWEETIOs, 2CB-5-EtO was not described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved) or in his 2003 book chapter on psychedelics.[2][3] In PiHKAL, Shulgin states that only 2CB-2-EtO and 2CB-2,5-DiEtO are known.[2] Similarly, in his 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, Shulgin states that 2CB-5-EtO is not in the published scientific literature.[5] Correspondingly, the drug is not included in Daniel Trachsel's 2013 book Phenethylamine: von der Struktur zur Funktion.[4] However, in a 1994 literature review on psychedelics, Shulgin states that 2CB-5-EtO is, in fact, known and active, with 2-fold lower potency compared to 2C-B, whereas 2CB-2-EtO has 5-fold lower potency than 2C-B.[1] The properties and effects of 2C-B-5-EtO were not otherwise described and remain unclear.[1]
A derivative of 2CB-5-EtO, ASR-2001 (2CB-5-PrO), in which the 5-ethoxy group has been lengthened to a 5-propoxy group, has been developed by the Alexander Shulgin Research Institute (ASRI) and is being investigated for potential medical use as a non-hallucinogenic mild stimulant-like medication.[6][7][8][9][10][11]
2CB-5-EtO was first described in the literature by Shulgin in 1994.[1] It is likely to have been developed and tested by Darrell Lemaire, with publication via personal communication with Shulgin.[3][12][13][14][15] The drug is a controlled substance in Canada under phenethylamine blanket-ban language.[16]